Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) saw a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 2,940,000 shares, a decrease of 6.7% from the January 15th total of 3,150,000 shares. Based on an average daily volume of 708,000 shares, the days-to-cover ratio is presently 4.2 days.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wolfe Research lowered Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research report on Tuesday, November 12th. Royal Bank of Canada reiterated an "outperform" rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 11th. Chardan Capital reiterated a "buy" rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. HC Wainwright reiterated a "buy" rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Finally, Sanford C. Bernstein lowered their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $299.48.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded up $1.98 during mid-day trading on Thursday, reaching $252.49. 727,787 shares of the company traded hands, compared to its average volume of 695,015. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The firm has a market cap of $32.69 billion, a PE ratio of -116.36 and a beta of 0.35. The stock has a fifty day simple moving average of $253.89 and a 200-day simple moving average of $263.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Equities research analysts anticipate that Alnylam Pharmaceuticals will post -1.94 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CMO Pushkal Garg sold 1,682 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $422,148.36. Following the completion of the transaction, the chief marketing officer now directly owns 17,457 shares in the company, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,356 shares of company stock valued at $22,498,551 in the last quarter. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ALNY. Huntington National Bank grew its position in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 45 shares during the last quarter. Larson Financial Group LLC grew its position in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 73 shares during the last quarter. Hollencrest Capital Management acquired a new position in Alnylam Pharmaceuticals in the third quarter worth approximately $29,000. R Squared Ltd acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $33,000. Finally, OFI Invest Asset Management acquired a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $35,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.